DK2675794T3 - Selektive fak-inhibitorer - Google Patents
Selektive fak-inhibitorer Download PDFInfo
- Publication number
- DK2675794T3 DK2675794T3 DK12705384.1T DK12705384T DK2675794T3 DK 2675794 T3 DK2675794 T3 DK 2675794T3 DK 12705384 T DK12705384 T DK 12705384T DK 2675794 T3 DK2675794 T3 DK 2675794T3
- Authority
- DK
- Denmark
- Prior art keywords
- fax
- inhibitors
- selective
- selective fax
- fax inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161443773P | 2011-02-17 | 2011-02-17 | |
| US201161523489P | 2011-08-15 | 2011-08-15 | |
| US201161579729P | 2011-12-23 | 2011-12-23 | |
| PCT/GB2012/000176 WO2012110774A1 (en) | 2011-02-17 | 2012-02-17 | Selective fak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2675794T3 true DK2675794T3 (da) | 2019-05-06 |
Family
ID=45755400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12705384.1T DK2675794T3 (da) | 2011-02-17 | 2012-02-17 | Selektive fak-inhibitorer |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US9174946B2 (da) |
| EP (1) | EP2675794B1 (da) |
| JP (1) | JP5937112B2 (da) |
| CN (1) | CN103534240B (da) |
| AU (1) | AU2012216894B2 (da) |
| CA (1) | CA2827172C (da) |
| DK (1) | DK2675794T3 (da) |
| ES (1) | ES2724525T3 (da) |
| WO (1) | WO2012110774A1 (da) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010034699A1 (de) * | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| DK2675794T3 (da) * | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| WO2012110773A1 (en) | 2011-02-17 | 2012-08-23 | Cancer Therapeutics Crc Pty Limited | Fak inhibitors |
| WO2014027199A1 (en) * | 2012-08-14 | 2014-02-20 | Cancer Therapeutics Crc Pty Ltd | Fak and flt3 inhibitors |
| HK1209105A1 (en) * | 2012-08-17 | 2016-03-24 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| CA2882270A1 (en) | 2012-08-17 | 2014-02-20 | Cancer Therapeutics Crc Pty Limited | Vegfr3 inhibitors |
| US10106834B2 (en) | 2013-10-09 | 2018-10-23 | The General Hospital Corporation | Methods of diagnosing and treating B cell acute lymphoblastic leukemia |
| CN107235931B (zh) * | 2017-07-11 | 2019-09-24 | 大连医科大学 | 新型嘧啶类抗肿瘤化合物及其制备方法与用途 |
| CN109503398B (zh) * | 2018-12-19 | 2021-07-02 | 江苏智远科创科技有限公司 | 一种n-甲基-4-甲氧基苯胺的制备方法 |
| AU2020245902B2 (en) * | 2019-03-28 | 2025-01-02 | Amplia Therapeutics Limited | A salt and crystal form of a FAK inhibitor |
| AU2020335937A1 (en) | 2019-08-31 | 2022-03-24 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Peptide inhibitors of focal adhesion kinase activity and uses thereof |
| EP4157278A4 (en) * | 2020-05-28 | 2024-07-03 | Amplia Therapeutics Limited | Methods of treating pulmonary fibrosis |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026097145A1 (en) * | 2024-11-11 | 2026-05-15 | Amplia Therapeutics Limited | Fak inhibitors |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| ES2284200T3 (es) | 1997-02-12 | 2007-11-01 | Electrophoretics Limited | Marcadores proteicos para cancer de pulmon y uso de los mismos. |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU5438299A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
| GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| PT1244647E (pt) | 1999-11-05 | 2006-10-31 | Astrazeneca Ab | Derivados de quinazolina como inibidores de vegf |
| HRP20020751B1 (hr) | 2000-02-15 | 2011-01-31 | Sugen | Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004886D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| JP4460292B2 (ja) * | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| SI1625121T1 (sl) | 2002-12-20 | 2010-04-30 | Pfizer Prod Inc | Derivati pirimidina za zdravljenje abnormalne rasti celic |
| US7109337B2 (en) | 2002-12-20 | 2006-09-19 | Pfizer Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| ATE542801T1 (de) | 2003-08-15 | 2012-02-15 | Novartis Ag | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine |
| PL1663991T3 (pl) | 2003-09-05 | 2007-04-30 | Pfizer Prod Inc | Selektywna synteza CF3 – podstawionych pirymidyn |
| MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| MXPA06013164A (es) | 2004-05-14 | 2007-02-13 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento de crecimiento de celulas anormal. |
| GB0419161D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419160D0 (en) | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| WO2006076442A2 (en) | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives |
| CA2632149C (en) | 2005-12-01 | 2011-11-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2681038A1 (en) | 2007-03-16 | 2008-09-25 | University Of Florida Research Foundation | Kinase protein binding inhibitors |
| EP2134689B1 (en) | 2007-03-16 | 2014-04-23 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| DK2146779T3 (da) | 2007-04-18 | 2016-11-28 | Pfizer Prod Inc | Sulfonylamid-derivater til behandling af unormal cellevækst. |
| EP2065380A1 (en) | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
| US8461147B2 (en) | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| WO2009105498A1 (en) | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| JP2011523646A (ja) | 2008-05-21 | 2011-08-18 | アリアド・ファーマシューティカルズ・インコーポレイテッド | キナーゼ阻害剤としてのリン誘導体 |
| CN102124000B (zh) | 2008-06-17 | 2014-09-17 | 阿斯利康(瑞典)有限公司 | 吡啶化合物 |
| JO3067B1 (ar) | 2008-10-27 | 2017-03-15 | Glaxosmithkline Llc | بيرميدينات بيرازولو امينو كمثبطات ل fak |
| UY32240A (es) | 2008-11-14 | 2010-06-30 | Boeringer Ingelheim Kg | Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones. |
| AR074210A1 (es) | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina como inhibidores de ptk2-quinasa |
| TW201024281A (en) | 2008-11-24 | 2010-07-01 | Boehringer Ingelheim Int | New compounds |
| US20110071158A1 (en) | 2009-03-18 | 2011-03-24 | Boehringer Ingelheim International Gmbh | New compounds |
| WO2010126922A1 (en) | 2009-04-30 | 2010-11-04 | Glaxosmithkline Llc | Benzimidazolecarboxamides as inhibitors of fak |
| US8410126B2 (en) | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| TW201100441A (en) | 2009-06-01 | 2011-01-01 | Osi Pharm Inc | Amino pyrimidine anticancer compounds |
| WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| EP2464642A4 (en) | 2009-08-12 | 2013-01-09 | Poniard Pharmaceuticals Inc | PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG |
| US8466155B2 (en) | 2009-10-02 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Pyrimidines |
| KR101147550B1 (ko) | 2009-10-22 | 2012-05-17 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 가지는 2,7-치환된 티에노［3,2-ｄ］피리미딘 화합물 |
| CA2803004A1 (en) | 2010-06-29 | 2012-01-12 | Poniard Pharmaceuticals, Inc. | Oral formulations of kinase inhibitors |
| CN103168037A (zh) | 2010-06-30 | 2013-06-19 | 博尼亚德医药品股份有限公司 | 激酶抑制剂的合成和用途 |
| DE102010034699A1 (de) | 2010-08-18 | 2012-02-23 | Merck Patent Gmbh | Pyrimidinderivate |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| WO2012045195A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
| WO2012045194A1 (en) | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| DK2675794T3 (da) * | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
-
2012
- 2012-02-17 DK DK12705384.1T patent/DK2675794T3/da active
- 2012-02-17 JP JP2013553996A patent/JP5937112B2/ja active Active
- 2012-02-17 US US13/985,741 patent/US9174946B2/en active Active
- 2012-02-17 WO PCT/GB2012/000176 patent/WO2012110774A1/en not_active Ceased
- 2012-02-17 EP EP12705384.1A patent/EP2675794B1/en active Active
- 2012-02-17 CN CN201280018816.6A patent/CN103534240B/zh active Active
- 2012-02-17 ES ES12705384T patent/ES2724525T3/es active Active
- 2012-02-17 CA CA2827172A patent/CA2827172C/en active Active
- 2012-02-17 AU AU2012216894A patent/AU2012216894B2/en active Active
- 2012-07-06 US US13/542,917 patent/US9120761B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN103534240A (zh) | 2014-01-22 |
| EP2675794A1 (en) | 2013-12-25 |
| AU2012216894B2 (en) | 2016-07-14 |
| AU2012216894A1 (en) | 2013-09-05 |
| US20130324546A1 (en) | 2013-12-05 |
| US9174946B2 (en) | 2015-11-03 |
| JP5937112B2 (ja) | 2016-06-22 |
| EP2675794B1 (en) | 2019-02-13 |
| CA2827172C (en) | 2019-02-26 |
| US20130022594A1 (en) | 2013-01-24 |
| ES2724525T3 (es) | 2019-09-11 |
| CN103534240B (zh) | 2015-12-09 |
| WO2012110774A1 (en) | 2012-08-23 |
| JP2014505719A (ja) | 2014-03-06 |
| CA2827172A1 (en) | 2012-08-23 |
| US9120761B2 (en) | 2015-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181786T1 (hr) | Inhibitori aktivacije t-stanica | |
| DK2685986T3 (da) | Glucosylceramidsyntasehæmmer | |
| DK3178818T3 (da) | Pyrazolylquinoxalinkinasehæmmere | |
| EP2715659A4 (en) | ABOUT FEED | |
| DK2769050T3 (da) | Propsensor | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| EP2752374A4 (en) | gooseneck | |
| EP2795884A4 (en) | Audio conferencing | |
| BR112014000879A2 (pt) | deflegmador | |
| DK3272861T3 (da) | Alpha-galactosidase-sammensætninger | |
| EP2701512A4 (en) | Aldosterone synthase inhibitors | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| EP2723481A4 (en) | STRÖMUNGSKOMPENSATOR | |
| EP2786752A4 (en) | Ropinirole-containing adhesive patch | |
| DK3141251T3 (da) | Koloskopi - forberedelse | |
| EP2708561A4 (en) | BIO-PIN | |
| EP2695208A4 (en) | MICRO THERMOCOUPLE | |
| EP2715068A4 (en) | Tunneling apparatus | |
| EP2738148A4 (en) | RECIPROCAL LOCKING BLOCK | |
| EP2762923A4 (en) | RADIATION MEASURING DEVICE | |
| DE112011104936A5 (de) | Stanzstauchniet | |
| EP2760803A4 (en) | Geopolymer product | |
| DE112012000958A5 (de) | Handsäge | |
| FI20125740L (fi) | Liitin |